References
- Behin A, Hoang-Xuan K, Carpentier AF. Primary brain tumours in adults. Lancet 2003; 361: 323–331
- Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Contr Rel 2001; 74: 63–67
- Brem H, Piantadosi S, Burger PC. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995; 345: 1008–1012
- Cutler DJ. Numerical deconvolution by least squares: Use of prescribed input functions. J Pharmacokinet Biopharm 1978; 6: 227–231
- Emerich DF, Winn SR, Hu Y, Marsh J, Snodgrass P, LaFreniere D, Wiens T, Hasler BP, Bartus RT. Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implntation into the cavity wall of debulked tumors. Pharm Res 2000; 17: 767–775
- Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 2000; 53: 458–464
- Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002; 41: 403–419
- Fung LK, Shin M, Tyler B, Brem H, Saltzman WM. Chemotherapeutic drugs released from polymers: Distribution of 1,3-bis(2-chloroethyl-1-nitrosourea in the rat brain. Pharm Res 1996; 13: 671–683
- Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1980; 50: 874–875
- Lawson HC, Sampath P, Bohan E, Park MC, Hussain N, Olivi A, Weingart J, Kleinberg L, Brem H. Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol. 2006, Available online at http://www.springerlink.com (Accessed 8 November 2006)
- Lesniak MS, Langer R, Brem H. Drug delivery to tumors of the central nervous system. Curr Neurol Neurosci Rep 2001; I: 210–218
- Loo TL, Dion RL, Dixon RL, Rale DP. The antitumor agent 1, 3-bis-(2-chloroethyl)-1-nitrosoures. J. Phar. Sci. 1966; 55: 492–498
- Pharma MGI, [Internet] Bloomington, MN, USA. 2006. Gliadel® wafer. Technical report. Available online at: http://www.gliadel.com (Accessed 4 February 2008)
- Rainov NG, Soling A, Heidecke V. Novel therapies for malignant gliomas: A local affair? Neurosurg Focus 20:E9. 2006, Available online at http://www.medscape.com (Accessed 8 November 2006)
- Saini M, Roser F, Samii M, Bellinzona M. A model for intratumoural chemotherapy in the rat brain. Acta Neurochirurg 2004; 146: 731–734
- Seong H, Khang G, Choi S, Lee CO, Lee HB. BCNU-loaded poly(D,L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro. Int J Pharm 2003; 251: 1–12
- Torres AI, Benoit JP. Formulation of BCNU loaded microspheres: Influence of drug stability and solubility on the design of the microencapsulation procedure. J Microencapsulation 1996; 13: 41–51
- Ueda-Kawamitsu H, Lawson TA, Gwilt PR. In vitro pharmacokinetics and pharmacodynamics of 1,3-bis (2-chloroethyl)-1-nitrosoures (BCNU). Biochem Pharmacol 2002; 63: 1209–128
- Vogelhuber W, Spruss T, Bernhardt G, Buschaner A, Göpferich A. Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts. Int J Pharm 2002; 238: 111–121
- Wang CC, Li J, Teo CS. The delivery of BCNU to brain tumors. J Cont Rel 1999; 61: 21–41
- Wang HT, Palmer H, Linhardt RJ, Flanagan DR, Schmitt E. Degradation of poly(ester) microspheres. Biomaterials 1990; 11: 679–685
- Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochirurg 2006; 148: 269–275